Mannheimia haemolytica and Ovine Pneumonic Pasteurellosis: Etiology, Pathogenesis, Diagnosis, and Control

Introduction

Ovine pneumonic pasteurellosis, commonly referred to as shipping fever pneumonia or pleuropneumonia, represents one of the most economically significant infectious diseases affecting sheep worldwide. The primary etiological agent is Mannheimia haemolytica, a Gram-negative coccobacillus belonging to the family Pasteurellaceae. This bacterium is a commensal of the upper respiratory tract in healthy sheep but acts as an opportunistic pathogen when host defenses are compromised by environmental stressors or viral co-infections. The disease is characterized by acute fibrinous pleuropneumonia, often leading to rapid death or chronic debilitation [1, 2, 3]. Understanding the molecular mechanisms of pathogenesis, the landscape of diagnostic technologies, and evolving antimicrobial resistance profiles is critical for effective control.

Etiology

Mannheimia haemolytica is classified into two major biogroups (A and T) based on nicotinamide adenine dinucleotide (NAD) independence. In sheep, the A biogroup, particularly serotype A2, is most frequently isolated from pneumonic cases [4, 5]. The bacterium expresses a suite of virulence factors, including a leukotoxin (Lkt) that is a pore-forming RTX (repeats in toxin) cytotoxin specific for ruminant leukocytes, an outer membrane capsule, lipopolysaccharide (LPS), adhesins, and proteases [6, 7, 8]. The leukotoxin is considered the principal virulence determinant; it triggers apoptosis and necrosis of alveolar macrophages and neutrophils, leading to the release of pro-inflammatory cytokines and enzymes that damage pulmonary tissue.

The C-terminal domain of the leukotoxin has been shown to be immunogenic and protective in experimental vaccine settings [6]. Additionally, proteins such as NlpI and DsbA have been evaluated as recombinant fusion antigens for cross-protective immunity [9]. Pangenome analyses of M. haemolytica have identified genes that differentiate genotypes 1 and 2, which may correlate with host specificity and pathogenic potential [10].

Epidemiology

Mannheimia haemolytica is endemic in sheep populations globally, with carriage rates in the nasopharynx varying from 20% to over 80% in clinically healthy flocks. Disease outbreaks are typically precipitated by stress factors including transport, crowding, nutritional changes, inclement weather, and concurrent infections (e.g., Mycoplasma ovipneumoniae, respiratory viruses) [11, 12]. The interplay between M. ovipneumoniae and M. haemolytica is particularly important; the former can impair mucociliary clearance, facilitating invasion by the latter [11].

A longitudinal study of a low-biosecurity sheep flock demonstrated dynamic circulation and strain diversity of M. ovipneumoniae [11], which parallels the clonal diversity observed in M. haemolytica populations [13, 14]. Whole-genome sequencing of bovine isolates has revealed contagious transmission patterns among feedlot calves; similar studies in sheep are needed but likely follow analogous routes [14]. In northern China, molecular epidemiological surveys have identified a high prevalence of M. haemolytica in sheep with pneumonic lesions, with serotype A2 predominant [5]. Abattoir-based studies in Ethiopia and Ghana have also confirmed the isolation of M. haemolytica from ovine pneumonic lungs, often in mixed bacterial infections [2, 4].

Mannheimia haemolytica infections are not limited to sheep. This pathogen also causes significant disease in cattle, including dairy cow deaths, and is a core component of the bovine respiratory disease complex (BRDC) [1, 13, 15, 16, 14, 8, 12]. Cross-species transmission is possible, though host-adapted genotypes may limit this [10].

Clinical Signs and Pathology

The clinical presentation of ovine pneumonic pasteurellosis ranges from peracute to chronic. Peracute cases are characterized by sudden death without premonitory signs. Acute cases manifest as pyrexia (40-42 degrees C), profound depression, tachypnea, dyspnea with open-mouth breathing, nasal discharge (serous to mucopurulent), and a cough. Auscultation reveals harsh lung sounds, crackles, and wheezes over the cranioventral lung fields.

Pathologically, the disease is a fibrinous pleuropneumonia. Gross lesions include consolidation of the cranioventral lung lobes (often bilateral), with a firm, red-to-grey hepatization. A hallmark is the presence of copious fibrin strands on the pleural surface and within the pleural cavity, yielding the pleuropneumonia designation. Cut surfaces of affected lung show a marbled pattern due to interlobular septal edema and fibrin deposition. Histopathology reveals intense neutrophilic infiltration, fibrin exudation, necrosis of alveolar septa, and thrombosis of pulmonary capillaries.

Pathogenesis

The pathogenesis of Mannheimia haemolytica pneumonia is a multifactorial process. Following stress-induced immunosuppression and viral damage to the respiratory epithelium (e.g., by parainfluenza-3 virus or respiratory syncytial virus), the bacterium proliferates in the lower respiratory tract. The leukotoxin (Lkt) binds to the CD18 subunit of beta2-integrins on ruminant leukocytes, causing pore formation and cell lysis. This triggers a massive release of inflammatory mediators, including interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-alpha), and leukotrienes, which further amplify tissue damage [17].

Catecholamines (epinephrine and norepinephrine) released during stress have been shown to increase the growth of M. haemolytica and upregulate the expression of adhesins and proteases, directly linking stress to enhanced virulence [7]. The bacterium also produces outer membrane vesicles (OMVs) that carry protein cargoes differentially packaged in response to host factors such as lactoferrin; these OMVs may modulate host immune responses [8]. Host genetic factors also play a role. For example, the interferon-inducible protein IFI204 (p204 in mice) restricts M. haemolytica pneumonia by eliciting gasdermin D-dependent inflammasome signaling and pyroptosis in macrophages [17]. Studies in Hainan Black goats have shown that peripheral blood mononuclear cells (PBMCs) mount a specific immune response involving both humoral and cellular arms during infection [18].

Diagnostics: Mannheimia haemolytica Sheep Pneumonic Pasteurellosis Pleuropneumonia

A definitive diagnosis of pneumonic pasteurellosis requires laboratory confirmation. A review of diagnostic technologies for M. haemolytica highlights a spectrum of methods [19].

Conventional Bacteriology

Isolation of M. haemolytica from lung tissue, pleural fluid, or nasal swabs is performed on blood agar or chocolate agar. Colonies typically appear as small, gray, mucoid, and non-hemolytic (or with a narrow zone of beta-hemolysis). Gram staining reveals Gram-negative coccobacilli. Biochemical profiles (e.g., oxidase-positive, catalase-positive, glucose fermentation) confirm the genus. Serotyping is performed using a slide agglutination test with specific antisera [4].

Molecular Diagnostics

Polymerase chain reaction (PCR) assays targeting the leukotoxin gene (lktA) or the 16S rRNA gene are widely used for specific detection. Quantitative real-time PCR (qPCR) allows for bacterial load estimation. Pangenome analysis and whole-genome sequencing provide high-resolution typing and detection of antimicrobial resistance genes [19, 10].

Serology

Enzyme-linked immunosorbent assays (ELISAs) that detect antibodies against M. haemolytica antigens (e.g., leukotoxin, outer membrane proteins) are available for serosurveillance, though they are less useful for diagnosing acute cases due to the rapid disease course [6, 9].

Diagnostic Workflow

The following Mermaid diagram outlines a diagnostic decision tree for suspected ovine pneumonic pasteurellosis.

flowchart TD
    A[Sheep with respiratory signs or sudden death], > B{Clinical exam & history}
    B, > C[Perform necropsy if dead / euthanized]
    C, > D[Gross lesions: cranioventral consolidation, fibrinous pleuritis]
    D, > E[Collect lung, pleural fluid, nasal swab]
    E, > F{Culture on blood agar / chocolate agar}
    F, > G[Gram stain, biochemical tests, serotyping]
    F, > H[PCR for lktA / 16S rRNA]
    H, > I[Confirmation of M. haemolytica]
    G, > I
    I, > J[Antimicrobial susceptibility testing (disk diffusion / MIC)]
    J, > K[Genotyping if needed (WGS / MLST)]
    K, > L[Epidemiological tracking & resistance profiling]
    E, > M[Consider co-pathogen testing: M. ovipneumoniae, respiratory viruses]

Treatment and Antimicrobial Resistance

Antimicrobial therapy is the mainstay of treatment for clinical cases. However, emerging resistance threatens efficacy. A pan-European survey of bovine and porcine respiratory pathogens found that M. haemolytica isolates generally exhibited low levels of resistance to most antimicrobial classes, but considerable geographic variability existed [16]. In Japan, temporal trends show increasing resistance to tetracyclines and macrolides in bovine isolates [15]. Similar trends are reported in sheep isolates from northwestern Ethiopia, where high resistance was observed against tetracycline and sulfonamides, while enrofloxacin and ceftiofur remained mostly effective [3]. An abattoir-based study in Ghana also documented multidrug resistance (MDR) among Pasteurella species from ovine lungs [2]. In northwestern China, sheep-derived isolates showed resistance to aminoglycosides and penicillins [5].

In light of rising resistance, alternative therapeutic approaches are being explored. Polycationic nanopeptide-fused endolysins have been developed to specifically lyse M. haemolytica, showing potent bactericidal activity in vitro and in vivo [20]. These lytic enzymes represent a novel strategy to circumvent traditional antibiotics.

Control and Prevention

Control of ovine pneumonic pasteurellosis relies on reducing stress, managing co-infections, vaccination, and biosecurity. Vaccines include inactivated bacterins, leukotoxin toxoids, and subunit vaccines. Recombinant proteins such as the C-terminal domain of leukotoxin [6] and fusion antigens (NlpI-DsbA) [9] have demonstrated protective efficacy in goats and mice, with potential cross-species utility. Intranasal administration of zinc and vitamin A has been investigated as a supportive immunomodulatory treatment in a bovine co-infection model (BRSV and M. haemolytica), showing altered immune responses but variable protection [12].

Biosecurity measures include quarantine of incoming animals, all-in-all-out management, proper ventilation in housing, and avoidance of overcrowding. Vaccination programs should be tailored to circulating serotypes, and antimicrobial stewardship should be practiced to slow the emergence of resistance.

References

[1] Anonymous. (2026). Mannheimia haemolytica causing dairy cow deaths in Northern Ireland. Vet Rec. https://pubmed.ncbi.nlm.nih.gov/42283312/

[2] Abdulai A, Emikpe BO, Folitse RD. (2026). Isolation and identification of Pasteurella species and other bacterial organisms from ovine pneumonic lungs and their antimicrobial susceptibility in Ghana: abattoir-based study. Front Vet Sci. https://pubmed.ncbi.nlm.nih.gov/42182917/

[3] Yihunie FB, Ibrahim SM, Ali DA, et al. (2026). Molecular Detection and Antibiotic Susceptibility Profiling of Mannheimia haemolytica Isolates From Pneumonic Pasteurellosis Suspected Cases of Sheep in Northwestern Ethiopia. Vet Med Sci. https://pubmed.ncbi.nlm.nih.gov/41915146/

[4] Dubie T, Abera B, Ebrahim OA, et al. (2026). Isolation and Identification of Pasteurella Species From Pneumonic Cases of Ovine and Caprine in Selected Districts of Afar Region, Ethiopia. Vet Med Sci. https://pubmed.ncbi.nlm.nih.gov/41508805/

[5] Wang C, Dou L, Wang J, et al. (2025). Molecular Epidemiology and Antibiotic Resistance of Sheep-Derived Mannheimia haemolytica in Northwestern China. Animals (Basel). https://pubmed.ncbi.nlm.nih.gov/41375550/

[6] Doan TD, Laohasatian T, Wu HC, et al. (2025). Protective efficacy of the recombinantly expressed C-terminal domain of Mannheimia haemolytica leukotoxin in mice and goats. J Vet Res. https://pubmed.ncbi.nlm.nih.gov/41497460/

[7] Rosales-Islas V, Montes-García JF, Ramírez-Paz-Y-Puente GA, et al. (2026). Epinephrine and norepinephrine increase the growth and expression of adhesins and proteases in Mannheimia haemolytica. Microb Pathog. https://pubmed.ncbi.nlm.nih.gov/41412203/

[8] Avalos-Gómez C, Aguilar-Chaparro MA, Ríos-Castro E, et al. (2026). Differences between protein cargo in outer membrane vesicles released from Mannheimia haemolytica A2 in the presence and absence of bovine lactoferrin. J Proteomics. https://pubmed.ncbi.nlm.nih.gov/41236000/

[9] Xu S, Sun Y, Wei J, et al. (2025). Antigenicity analysis of the recombinant fusion proteins NlpI of Mannheimia haemolytica and DsbA of Pasteurella multocida. BMC Vet Res. https://pubmed.ncbi.nlm.nih.gov/41430668/

[10] Deschner D, Hill JE. (2025). Identification of genes that differentiate Mannheimia haemolytica genotypes 1 and 2 using a pangenome approach. PLoS One. https://pubmed.ncbi.nlm.nih.gov/41100528/

[11] Sajovitz-Grohmann F, Lichtmannsperger K, Brunthaler R, et al. (2026). Dynamic circulation and strain diversity of Mycoplasma ovipneumoniae in a low-biosecurity sheep flock. Vet Microbiol. https://pubmed.ncbi.nlm.nih.gov/42208337/

[12] Rients EL, Franco CE, Hansen SL, et al. (2025). Intranasal zinc and vitamin A treatments alter response to bovine respiratory syncytial virus and Mannheimia haemolytica co-infection. Transl Anim Sci. https://pubmed.ncbi.nlm.nih.gov/40927235/

[13] Hacker ND, Scott MA, Pinnell LJ, et al. (2026). Exploring clonality of Mannheimia haemolytica in beef cattle. Microbiol Spectr. https://pubmed.ncbi.nlm.nih.gov/42043314/

[14] Snyder ER, Younes JA, Bird EM, et al. (2026). Investigating contagious transmission of Mannheimia haemolytica in feedlot calves by leveraging whole genome sequences of a unique isolate collection. Vet Microbiol. https://pubmed.ncbi.nlm.nih.gov/41780376/

[15] Ueno Y, Hoshinoo K, Suwa T, et al. (2026). Temporal trends of antimicrobial resistance and resistance genes in Mannheimia haemolytica from cattle in Japan. Vet Microbiol. https://pubmed.ncbi.nlm.nih.gov/41916129/

[16] de Jong A, Temmerman R, Rose M, et al. (2026). Pan-European analysis shows stable, low antimicrobial resistance in most bovine and porcine respiratory tract pathogens. Front Microbiol. https://pubmed.ncbi.nlm.nih.gov/41809594/

[17] Li JQ, Zhao Y, Li ZY, et al. (2025). IFI204 Restricts Mannheimia haemolytica Pneumonia via Eliciting Gasdermin D-Dependent Inflammasome Signaling. Microorganisms. https://pubmed.ncbi.nlm.nih.gov/41304242/

[18] Wang Z, Wu L, Qian H, et al. (2026). PBMCs of Hainan Black goats mediating immune response to resist the infection of Mannheimia haemolytica. Microb Pathog. https://pubmed.ncbi.nlm.nih.gov/41232700/

[19] Wang C, Bai X, Wang J, et al. (2025). Exploring the diagnostic landscape of Mannheimia haemolytica: technologies, applications, and perspectives. Front Microbiol. https://pubmed.ncbi.nlm.nih.gov/41244692/

[20] Moqaddes S, Du H, Lin J, et al. (2026). Polycationic nanopeptide-fused endolysins for the control of Mannheimia haemolytica. Appl Microbiol Biotechnol. https://pubmed.ncbi.nlm.nih.gov/42104005/